Protalix BioTherapeutics annual return on equity
2010
2016
2023
2024
2025
Protalix BioTherapeutics Return on Equity (ROE) Growth & History (PLX)
Protalix BioTherapeutics's return on equity was −14.44% for fiscal 2025.
View full Protalix BioTherapeutics company overviewProtalix BioTherapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −14.44% | −22.08 pp |
| 2024 | 2024-12-31 | 7.64% | −64.86 pp |
| 2023 | 2023-12-31 | 72.50% | — |
| 2016 | 2016-12-31 | −6,411.57% | — |
| 2010 | 2010-12-31 | −1,271.84% | — |
Protalix BioTherapeutics quarterly return on equity
Q2.12
Q3.12
Q4.12
Q1.16
Q2.21
Q3.21
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 5.45% | +5.10 pp |
| Q1 2026 | 2026-03-31 | 31.73% | +39.92 pp |
| Q4 2025 | 2025-12-31 | −10.88% | −28.05 pp |
| Q3 2025 | 2025-09-30 | 4.58% | −6.03 pp |
| Q2 2025 | 2025-06-30 | 0.34% | +7.89 pp |
| Q1 2025 | 2025-03-31 | −8.19% | +6.32 pp |
| Q4 2024 | 2024-12-31 | 17.17% | +34.00 pp |
| Q3 2024 | 2024-09-30 | 10.61% | +15.40 pp |
| Q2 2024 | 2024-06-30 | −7.55% | −104.22 pp |
| Q1 2024 | 2024-03-31 | −14.51% | — |
| Q4 2023 | 2023-12-31 | −16.83% | — |
| Q3 2023 | 2023-09-30 | −4.79% | — |
| Q2 2023 | 2023-06-30 | 96.67% | — |
| Q3 2021 | 2021-09-30 | −207.15% | — |
| Q2 2021 | 2021-06-30 | −122.55% | — |
| Q1 2016 | 2016-03-31 | −127.16% | — |
| Q4 2012 | 2012-12-31 | −1,396.04% | — |
| Q3 2012 | 2012-09-30 | −86.73% | — |
| Q2 2012 | 2012-06-30 | 1,371.55% | — |
Protalix BioTherapeutics return on equity trends
Between the periods ended 2010-12-31 and 2025-12-31, Protalix BioTherapeutics's return on equity increased from −1,271.84% to −14.44%, a change of +1257.40 percentage points. The latest reported quarter, Q2 2026, shows 5.45%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protalix BioTherapeutics source filings ↗